Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057278 · ClinicalTrials.gov registry record · Phase 2
Gabapentin in Fibromyalgia Trial (GIFT)
A Phase 2 study of Fibromyalgia, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT00057278 is a Phase 2 study of Fibromyalgia that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The registered enrollment target is 150 participants, below the 177-participant average among 76 other Fibromyalgia trials with a reported enrollment target (15% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00057278, a Phase 2 study of Fibromyalgia, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will assess the safety and effectiveness of the drug gabapentin in reducing pain associated with primary fibromyalgia.
Conditions Studied
Interventions
- DRUG gabapentin
Study Locations (3)
Massachusetts
- McLean Hospital/Harvard Medical School (must live in the Boston, MA area) - Belmont
- Newton-Wellesley Hospital (must live in the Boston, MA area) - Newton
Ohio
- University of Cincinnati College of Medicine, Department of Psychiatry (must live in the Cincinnati, OH area) - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)93 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057278
The ClinicalTrials.gov registry entry for NCT00057278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 76 other Fibromyalgia trials with a reported enrollment target (15% lower). The listed sponsor is National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 1 intervention - of which gabapentin is the first listed.
NCT00057278 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT00057278 about?
NCT00057278 is a clinical study titled "Gabapentin in Fibromyalgia Trial (GIFT)". This study will assess the safety and effectiveness of the drug gabapentin in reducing pain associated with primary fibromyalgia.
What is the current status of trial NCT00057278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-03. Estimated completion is 2006-01.
What conditions does trial NCT00057278 study?
This clinical trial studies the following conditions: Fibromyalgia.
What interventions are being tested in trial NCT00057278?
The interventions under investigation include: gabapentin (DRUG).
Who is sponsoring clinical trial NCT00057278?
This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00057278 being conducted?
This trial has 3 study locations across Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nitrous Oxide as Treatment for Fibromyalgia
RECRUITING · Phase 2
-
Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia
COMPLETED · Phase 2
-
Dextromethorphan in Fibromyalgia
COMPLETED · Phase 2
-
Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment
COMPLETED · Phase 2
-
Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain
COMPLETED · Phase 2
-
Heart Rate Variability in Response to Metformin Challenge
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.